TY - JOUR
T1 - Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment
AU - Gu, Yanyun
AU - Wang, Xiaokai
AU - Li, Junhua
AU - Zhang, Yifei
AU - Zhong, Huanzi
AU - Liu, Ruixin
AU - Zhang, Dongya
AU - Feng, Qiang
AU - Xie, Xiaoyan
AU - Hong, Jie
AU - Ren, Huahui
AU - Liu, Wei
AU - Ma, Jing
AU - Su, Qing
AU - Zhang, Hongmei
AU - Yang, Jialin
AU - Wang, Xiaoling
AU - Zhao, Xinjie
AU - Gu, Weiqiong
AU - Bi, Yufang
AU - Peng, Yongde
AU - Xu, Xiaoqiang
AU - Xia, Huihua
AU - Li, Fang
AU - Xu, Xun
AU - Yang, Huanming
AU - Xu, Guowang
AU - Madsen, Lise
AU - Kristiansen, Karsten
AU - Ning, Guang
AU - Wang, Weiqing
N1 - Publisher Copyright:
© 2017 The Author(s).
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.
AB - Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.
UR - https://www.scopus.com/pages/publications/85035341770
U2 - 10.1038/s41467-017-01682-2
DO - 10.1038/s41467-017-01682-2
M3 - 文章
C2 - 29176714
AN - SCOPUS:85035341770
SN - 2041-1723
VL - 8
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1785
ER -
